Research programme: IL-22RA monoclonal antibody - Merck Serono

Drug Profile

Research programme: IL-22RA monoclonal antibody - Merck Serono

Alternative Names: Interleukin 22 subunit alpha receptor - ZymoGenetics; Psoriasis therapy - ZymoGenetics

Latest Information Update: 05 Sep 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ZymoGenetics
  • Developer Merck Serono
  • Class Monoclonal antibodies; Proteins
  • Mechanism of Action Interleukin 20 receptor antagonists; Interleukin 22 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Psoriasis

Most Recent Events

  • 13 Oct 2010 ZymoGenetics has been acquired by Bristol-Myers Squibb
  • 08 Sep 2010 Bristol-Myers Squibb agrees to acquire ZymoGenetics ,
  • 25 Mar 2009 Preclinical development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top